Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation

Abstract: Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor family. PPARs function as regulators of lipid and lipoprotein metabolism and glucose homeostasis and influence cellular proliferation, differentiation and apoptosis. PPARα is highly expressed in tissues such as liver, muscle, kidney and heart, where it stimulates the β-oxidative degradation of fatty acids. PPARγ is predominantly expressed in intestine and adipose tissue. PPARγ triggers adipocyte differentiation and promotes lipid storage. The hypolipidemic fibrates and the antidiabetic glitazones are synthetic ligands for PPARα and PPARγ, respectively. Furthermore, fatty acids and eicosanoids are natural PPAR ligands: PPARα is activated by leukotriene B4, whereas prostaglandin J2 is a PPARγ ligand. These observations suggested a potential role for PPARs not only in metabolic but also in inflammation control. The first evidence for a role of PPARα in inflammation control came from the demonstration that PPARα deficient mice display a prolonged response to inflammatory stimuli. It was suggested that PPARα deficiency results in a reduced β-oxidative degradation of these inflammatory fatty acid derivatives. More recently, PPAR activators were shown to inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-8, TNFα and metalloproteases) by negatively interfering with the NF-κB, STAT and AP-1 signalling pathways. PPAR activators exert these anti-inflammatory activities in different immunological and vascular wall cell types such as monocyte/macrophages, endothelial, epithelial and smooth muscle cells in which PPARs are expressed. These recent findings indicate a modulatory role for PPARs in the control of the inflammatory response with potential therapeutic applications in inflammation-related diseases, such as atherosclerosis and inflammatory bowel disease.

[1]  B. Spiegelman.  PPARγ in Monocytes: Less Pain, Any Gain? , 1998, Cell.

[2]  P. Colville-Nash,et al.  Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. , 1998, Journal of immunology.

[3]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[4]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[5]  J. Auwerx,et al.  Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* , 1997, The Journal of Biological Chemistry.

[6]  V. Laudet,et al.  Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. , 1999, Molecular endocrinology.

[7]  P. Libby,et al.  PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells , 1999 .

[8]  K. Beier,et al.  TNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver. , 1997, FEBS letters.

[9]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[10]  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[11]  A. Tedgui,et al.  CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.

[12]  T. Ishida,et al.  Thiazolidinedione inhibits production of RANTES in a cytokine‐treated human lung epithelial cell line , 1999, FEBS letters.

[13]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[14]  D. Faxon,et al.  Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. , 1996, The Journal of clinical investigation.

[15]  J. Auwerx,et al.  Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[16]  G. Natoli,et al.  Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase , 2000, Nature.

[17]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[18]  M. Nishizawa,et al.  Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between Jun and peroxisome proliferator-activated receptor alpha. , 1995, Cancer research.

[19]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[20]  J. Gustafsson,et al.  Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. , 1996, Biochemical and biophysical research communications.

[21]  B. Sobel.  Insulin resistance and thrombosis: a cardiologist's view. , 1999, American Journal of Cardiology.

[22]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. , 1998, Nature.

[23]  D. Kelly,et al.  Fatty Acids Activate Transcription of the Muscle Carnitine Palmitoyltransferase I Gene in Cardiac Myocytes via the Peroxisome Proliferator-activated Receptor α* , 1998, The Journal of Biological Chemistry.

[24]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[25]  J. Auwerx,et al.  Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. , 1999, Gastroenterology.

[26]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[27]  G. Zimmerman,et al.  Peroxisome Proliferators Enhance Cyclooxygenase-2 Expression in Epithelial Cells* , 1999, The Journal of Biological Chemistry.

[28]  W. Hsueh,et al.  Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[29]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[30]  Y. Hattori,et al.  Smooth Muscle Cells , 2021, Reference Module in Biomedical Sciences.

[31]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[32]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[33]  J. Auwerx,et al.  Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. , 1993, European journal of biochemistry.

[34]  X. Yang,et al.  Member of the peroxisome proliferator–activated receptor family of transcription factors is differentially expressed by oligodendrocytes , 1998, Journal of neuroscience research.

[35]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[36]  H. Itoh,et al.  Down regulation of peroxisome proliferator-activated receptorγ expression by inflammatory cytokines and its reversal by thiazolidinediones , 1999, Diabetologia.

[37]  M. Gerritsen,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in Vivo * , 1999, The Journal of Biological Chemistry.

[38]  T. Watanabe,et al.  Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. , 1999, Biochemical and biophysical research communications.

[39]  T. Ishida,et al.  Thiazolidinedione inhibits the production of monocyte chemoattractant protein‐1 in cytokine‐treated human vascular endothelial cells , 1999, FEBS letters.

[40]  A. Brouillet,et al.  Interleukin 1β Induces Type II-secreted Phospholipase A2 Gene in Vascular Smooth Muscle Cells by a Nuclear Factor κB and Peroxisome Proliferator-activated Receptor-mediated Process* , 1999, The Journal of Biological Chemistry.

[41]  T. Kooistra,et al.  Fibrate-modulated Expression of Fibrinogen, Plasminogen Activator Inhibitor-1 and Apolipoprotein A-I in Cultured Cynomolgus Monkey Hepatocytes , 1998, Thrombosis and Haemostasis.

[42]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[43]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[44]  B. Spiegelman,et al.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. , 1995, Cell.

[45]  P. Grimaldi,et al.  Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. , 1993, The Journal of biological chemistry.

[46]  B. Spiegelman,et al.  Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. , 1996, Molecular endocrinology.

[47]  J. Auwerx,et al.  Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients , 1997, Diabetes.

[48]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[49]  D. Waxman,et al.  Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of pparalpha transcriptional activity mediated by stat5b. , 1999, The Journal of biological chemistry.

[50]  F. Hegardt,et al.  Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor* , 1998, The Journal of Biological Chemistry.

[51]  P. Libby,et al.  Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. , 1998, The American journal of pathology.

[52]  K. Beier,et al.  TNF‐α downregulates the peroxisome proliferator activated receptor‐α and the mRNAs encoding peroxisomal proteins in rat liver , 1997 .

[53]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[54]  W. Wahli,et al.  Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA , 1997, The Journal of Biological Chemistry.

[55]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[56]  A. Hamsten,et al.  Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.

[57]  A. Greenberg,et al.  The short- and long-term effects of tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)gamma2 gene expression and other adipocyte genes. , 1998, Molecular endocrinology.

[58]  J. Kastelein,et al.  Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients , 1997, Thrombosis and Haemostasis.

[59]  P. Libby,et al.  PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. , 1999, Circulation.

[60]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[61]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[62]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[63]  T. Olivecrona,et al.  Regulation of lipoprotein lipase. , 1993, Biochemical Society transactions.

[64]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[65]  P. Durrington,et al.  Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. , 1998, Atherosclerosis.

[66]  R. Stocker,et al.  Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins. , 1998, Biochemistry.

[67]  C. Ioannides,et al.  Induction of the cytochrome P450 I and IV families and peroxisomal proliferation in the liver of rats treated with benoxaprofen. Possible implications in its hepatotoxicity. , 1991, Biochemical pharmacology.

[68]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[69]  S. Noji,et al.  Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. , 1998, Biochemical and biophysical research communications.

[70]  J. Peters,et al.  Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). , 1998, The Journal of biological chemistry.

[71]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[72]  G. Ringold,et al.  Requirements for triggering of adipocyte differentiation by glucocorticoids and indomethacin. , 1987, Molecular endocrinology.

[73]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[74]  J. Peters,et al.  Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor α and γ Activators in a Tissue- and Inducer-specific Manner* , 1998, The Journal of Biological Chemistry.

[75]  P. Libby,et al.  PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .

[76]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[77]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[78]  A. Hamsten,et al.  Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[79]  W. Wahli,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society Differential Expression of Peroxisome Proliferator- Activated Receptor-�,-�, and- � during Rat , 2022 .

[80]  J. Peters,et al.  Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. , 1998, The Journal of biological chemistry.

[81]  B. Okopień,et al.  Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. , 1998, International journal of clinical pharmacology and therapeutics.

[82]  J. Auwerx,et al.  Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[83]  J. Lehmann,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[84]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[85]  T. Petrova,et al.  Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[86]  M. Díaz-Guerra,et al.  Inhibition of IκB Kinase and IκB Phosphorylation by 15-Deoxy-Δ12,14-Prostaglandin J2 in Activated Murine Macrophages , 2000, Molecular and Cellular Biology.

[87]  T. Mori,et al.  抗高脂血症薬フェノフィブラートの抗動脈硬化作用(I)コレステロール負荷ウサギにおける血清脂質低下作用を介さない抗動脈硬化作用 , 1995 .

[88]  J. Peters,et al.  Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.

[89]  A. Greenberg,et al.  The Short- and Long-Term Effects of Tumor Necrosis Factor-α and BRL 49653 on Peroxisome Proliferator-Activated Receptor (PPAR)γ2 Gene Expression and Other Adipocyte Genes , 1998 .

[90]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[91]  T. Watanabe,et al.  Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. , 1999, Biochemical and biophysical research communications.

[92]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.